Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial - Concepedia

Concepedia

Publication | Closed Access

Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial

54

Citations

19

References

2022

Year

Fabio Conforti, Paolo Andrea Zucali, Laura Pala, Chiara Catania, Vincenzo Bagnardi, Isabella Sala, Paolo Della Vigna, Matteo Perrino, Paola Zagami, Chiara Corti,

The Lancet Oncology

MedicineImmunologyPathologyImmune Checkpoint InhibitorAnti-cancer AgentCancer TreatmentPhase 2OncologyThymic Carcinomas

References

	Year	Citations

Page 1

Page 1